ABC转运体抑制联合地塞米松增强H3.3K27M突变弥漫性内生性桥脑胶质瘤的CED疗效
BACKGROUND: An impermeable blood-brain barrier and drug efflux via ATP-binding cassette (ABC) transporters such as p-glycoprotein may contribute to underwhelming efficacy of peripherally delivered agents to treat diffuse intrinsic pontine glioma (DIPG).…
要点
- CED达沙替尼可延长H3.3K27M突变DIPG模型的中位生存。
- K27M胶质瘤中ABCB1(p-糖蛋白)平均表达最高。
- 地塞米松加tariquidar预处理不改变CED药物分布,但增加肿瘤凋亡并改善生存。
核心结论
- ABC转运体抑制联合地塞米松可增强CED达沙替尼的疗效,增加肿瘤细胞凋亡并改善H3.3K27M突变DIPG模型的生存。
研究设计与样本
- 在转基因H3.3K27M突变小鼠DIPG模型中评估CED达沙替尼的疗效。
- 分析274名儿童中14种肿瘤类型的ABCB1(p-糖蛋白)mRNA表达。
- 在2株H3.3K27M突变细胞系中行达沙替尼、tariquidar与地塞米松的体外活力研究。
- 用MRI评估经tariquidar和地塞米松预处理的动物中CED输注液(钆/达沙替尼)的分布,并行凋亡的组织学评估。
主要发现
- ABCB1平均表达在K27M胶质瘤中最高。
- MRI显示地塞米松加tariquidar预处理组与单用CED达沙替尼组的输注弥散无差异。
临床怎么用
- 对H3.3K27M突变DIPG,CED局部输注达沙替尼并联合p-糖蛋白抑制与地塞米松可能增强疗效,但尚属临床前证据。
局限性
- 证据来自转基因小鼠模型与2株细胞系,尚需临床验证。
- ABCB1表达分析为儿童多肿瘤类型的mRNA数据,非DIPG治疗队列。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: An impermeable blood-brain barrier and drug efflux via ATP-binding cassette (ABC) transporters such as p-glycoprotein may contribute to underwhelming efficacy of peripherally delivered agents to treat diffuse intrinsic pontine glioma (DIPG). OBJECTIVE: To explore the pharmacological augmentation of convection-enhanced delivery (CED) infusate for DIPG. METHODS: The efficacy of CED dasatinib, a tyrosine kinase inhibitor, in a transgenic H3.3K27M mutant murine model was assessed. mRNA expression of ABCB1 (p-glycoprotein) was analyzed in 14 tumor types in 274 children. In Vitro viability studies of dasatinib, the p-glycoprotein inhibitor, tariquidar, and dexamethasone were performed in 2 H3.3K27M mutant cell lines. Magnetic resonance imaging (MRI) was used to evaluate CED infusate (gadolinium/dasatinib) distribution in animals pretreated with tariquidar and dexamethasone. Histological assessment of apoptosis was performed. RESULTS: Continuous delivery CED dasatinib improved median overall survival (OS) of animals harboring DIPG in comparison to vehicle (39.5 and 28.5 d, respectively; P = .0139). Mean ABCB1 expression was highest in K27M gliomas. In Vitro, the addition of tariquidar and dexamethasone further enhanced the efficacy of dasatinib (P < .001). In Vivo, MRI demonstrated no difference in infusion dispersion between animals pretreated with dexamethasone plus tariquidar prior to CED dasatinib compared to the CED dasatinib. However, tumor apoptosis was the highest in the pretreatment group (P < .001). Correspondingly, median OS was longer in the pretreatment group (49 d) than the dasatinib alone group (39 d) and no treatment controls (31.5 d, P = .0305). CONCLUSION: ABC transporter inhibition plus dexamethasone enhances the efficacy of CED dasatinib, resulting in enhanced tumor cellular apoptosis and improved survival in H3.3K27M mutant DIPG.
引用
- Tsvankin V, Hashizume R, Katagi H, et al. ABC Transporter Inhibition Plus Dexamethasone Enhances the Efficacy of Convection Enhanced Delivery in H3.3K27M Mutant Diffuse Intrinsic Pontine Glioma. Neurosurgery. 2020. PMID: 31225627. doi:10.1093/neuros/nyz212
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。